AMENDED AND RESTATED SECURED TERM NOTESecured Term Note • December 21st, 2023 • Scott John K Jr. • In vitro & in vivo diagnostic substances
This Amended and Restated Secured Term Note (the “Note”) amends and restates in its entirety that certain Secured Term Note dated April 10, 2022 made by the Borrower in favor of the Lender in the original principal amount of $2,500,000 (the “Original Note”), all of which was loaned to the Borrower. On June 29, 2023, the Borrower and the Lender agreed to exchange $1,073,600 principal amount of the Original Note for 12,200,000 shares of the Borrower’s common stock based on the closing stock price on June 28, 2023. On the date hereof, the Lender has agreed to forgive $100,000 of principal outstanding under the Original Note and to advance an additional loan in the principal amount of $750,000.00 pursuant to a separate secured convertible promissory note. In addition, the Borrower and the Lender have agreed to extend the maturity date of the Original Note for an additional 12 months.
loan and securities EXCHANGE AGREEMENTLoan and Securities Exchange Agreement • December 21st, 2023 • Scott John K Jr. • In vitro & in vivo diagnostic substances • Colorado
THIS LOAN AND SECURITIES EXCHANGE AGREEMENT (this “Agreement”) is made effective as of the 27th day of November, 2023 (the “Effective Date”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and John K. Scott, Jr., an individual residing in the State of Colorado (the “Investor”).
SECURITIES EXCHANGE AGREEMENT Effective as of August 24, 2022Securities Exchange Agreement • September 12th, 2022 • Scott John K Jr. • In vitro & in vivo diagnostic substances • Ohio
This Securities Exchange Agreement (this “Agreement”) is being entered into by John K. Scott, Jr. (the “Holder”), and Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the Holder’s subscription to purchase up to 2,400 Units (the “Purchased Units”) pursuant to and subject to the terms set forth in that certain Registration Statement on Form S-1, Registration No. 333-262691, as amended (the “Registration Statement”) and a Prospectus Supplement No. 1 dated August 18, 2022 (the “Prospectus Supplement”). Capitalized terms used but not defined herein have the definitions given to them in the Registration Statement.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 26th, 2020 • Scott John K Jr. • In vitro & in vivo diagnostic substances • New York
This Stock Purchase Agreement (this “Agreement”) is made and entered into as of February 13, 2020, by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and John Kim Scott (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 26th, 2020 • Scott John K Jr. • In vitro & in vivo diagnostic substances • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 13, 2020, by and between NAVIDEA BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and John K. Scott, Jr. (the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Stock Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SECOND AMENDMENT TO SECURITY AGREEMENTSecurity Agreement • December 21st, 2023 • Scott John K Jr. • In vitro & in vivo diagnostic substances
THIS SECOND AMENDMENT TO SECURITY AGREEMENT (this “Amendment”), dated as of November 27, 2023, is made by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation with an address of 4995 Bradenton Ave #240, Dublin, OH 43017 (“Debtor”) and John Kim Scott Jr., an individual (“Secured Party”).
June 29, 2023 John K. Scott, Jr.Term Note Repayment Agreement • July 5th, 2023 • Scott John K Jr. • In vitro & in vivo diagnostic substances
